Researchers from the University of Cambridge have developed an innovative urine test aimed at detecting early-stage lung cancer by identifying senescent cells, often referred to as “zombie cells.” These cells, which have ceased dividing but remain metabolically active, can contribute to inflammation and tumor progression. The test utilizes an injectable sensor that interacts with proteins released by these senescent cells, subsequently releasing a detectable compound into the urine. This non-invasive method holds promise for identifying lung cancer months or even years before noticeable symptoms emerge.
Early detection of lung cancer is crucial, as the disease often remains asymptomatic until advanced stages, making treatment more challenging. By focusing on the presence of senescent cells, this urine test offers a cost-effective and accessible alternative to traditional diagnostic methods like biopsies and imaging scans. The research team is currently conducting further studies to validate the test’s efficacy, with the goal of integrating it into routine clinical practice to improve early cancer detection and patient outcomes. Click for More Details
